- Home
- ARQT vs CABO Comparison
ARQT vs CABO Comparison
Compare ARQT & CABO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- CABO
- Stock Information
- Founded
- ARQT 2016
- CABO 1980
- Country
- ARQT United States
- CABO United States
- Employees
- ARQT N/A
- CABO N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- CABO Cable & Other Pay Television Services
- Sector
- ARQT Health Care
- CABO Telecommunications
- Exchange
- ARQT Nasdaq
- CABO Nasdaq
- Market Cap
- ARQT 1.7B
- CABO 1.4B
- IPO Year
- ARQT 2020
- CABO N/A
- Fundamental
- Price
- ARQT $13.04
- CABO $146.42
- Analyst Decision
- ARQT Strong Buy
- CABO Hold
- Analyst Count
- ARQT 6
- CABO 3
- Target Price
- ARQT $18.80
- CABO $231.00
- AVG Volume (30 Days)
- ARQT 2.1M
- CABO 302.4K
- Earning Date
- ARQT 05-06-2025
- CABO 05-01-2025
- Dividend Yield
- ARQT N/A
- CABO 8.06%
- EPS Growth
- ARQT N/A
- CABO N/A
- EPS
- ARQT N/A
- CABO N/A
- Revenue
- ARQT $212,819,000.00
- CABO $1,555,831,000.00
- Revenue This Year
- ARQT $61.15
- CABO N/A
- Revenue Next Year
- ARQT $37.98
- CABO N/A
- P/E Ratio
- ARQT N/A
- CABO N/A
- Revenue Growth
- ARQT 100.03
- CABO N/A
- 52 Week Low
- ARQT $6.99
- CABO $140.69
- 52 Week High
- ARQT $17.75
- CABO $437.00
- Technical
- Relative Strength Index (RSI)
- ARQT 40.51
- CABO 33.25
- Support Level
- ARQT $13.27
- CABO $142.63
- Resistance Level
- ARQT $14.30
- CABO $159.02
- Average True Range (ATR)
- ARQT 0.71
- CABO 9.26
- MACD
- ARQT -0.07
- CABO 1.50
- Stochastic Oscillator
- ARQT 10.94
- CABO 17.59
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About CABO Cable One Inc.
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.